Verona Pharma plc
VRNADelisted Oct 7, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001657312
Verona Pharma plc was delisted on Oct 7, 2025; its insiders filed their last Form 4 on Oct 8, 2025; 243 institutions reported holding it in 13F filings for Q3 2025, worth $8.57B in total; superinvestors Duquesne Family Office and Soros Fund Management held it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 243
- Q3 2025, −48 vs. previous quarter
- 13F value
- $8.57B
- Reported value at the end of Q3 2025
- Superinvestors holding
- 2
- At the end of Q3 2025
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2024
- $42.3M
- No comparable prior period
- Net income, FY2024
- -$173.4M
- No comparable prior period
- Free cash flow, FY2024
- -$122.8M
- No comparable prior period
- Revenue, Q2 FY2025
- $103.1M
- No comparable prior period
Revenue flow, FY2024
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2024: $173.4M (410.2% of revenue).
Superinvestors holding VRNA, Q3 2025
Go to the superinvestors tab2 superinvestors report holding Verona Pharma plc on Form 13F. Percentages are the stock's share of each portfolio.
Duquesne Family Office
Stanley Druckenmiller
2.7%
Verona Pharma plc's share of the portfolio
- Shares
- 1,002,080
- Value
- $106.9M
Soros Fund Management
George Soros
0.5%
Verona Pharma plc's share of the portfolio
- Shares
- 285,185
- Value
- $30.4M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Verona Pharma plc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 5, 2025 (view filing) | Aug 1 | 4 days | Cunningham KennethDirector | SSale | −10.8K | $13.14 | −$142.0K | −11.9%79.8K after | |
| Aug 5, 2025 (view filing) | Aug 1 | 4 days | Deschamps LisaDirector | SSale | −9.46K | $13.14 | −$124.4K | −10.0%84.9K after | |
| Aug 5, 2025 (view filing) | Aug 1 | 4 days | Fisher AndrewGeneral Counsel | SSale | −9.58K | $13.14 | −$125.9K | −2.2%417.9K after | |
| Aug 5, 2025 (view filing) | Aug 1 | 4 days | Hahn Mark WChief Financial Officer | SSale | −208.9K | $13.14 | −$2.75M | −1.6%12.5M after | 10b5-1 |
| Aug 5, 2025 (view filing) | Aug 1 | 4 days | Rickard Kathleen A.Chief Medical Officer | SSale | −58.3K | $13.14 | −$766.5K | −2.2%2.61M after | 10b5-1 |
| Aug 5, 2025 (view filing) | Aug 1 | 4 days | Ackermann ChristinaDirector | SSale | −1.81K | $13.14 | −$23.8K | −2.7%64.1K after | |
| Aug 5, 2025 (view filing) | Aug 1 | 4 days | Austwick MichaelDirector | SSale | −11.3K | $13.14 | −$148.3K | −47.0%12.7K after | |
| Aug 5, 2025 (view filing) | Aug 1 | 4 days | Brady James AloysiusDirector | SSale | −824 | $13.14 | −$10.8K | −3.4%23.2K after | |
| Aug 5, 2025 (view filing) | Aug 1 | 4 days | Zaccardelli DavidPresident and CEO | SSale | −208.9K | $13.14 | −$2.75M | −1.5%13.4M after | 10b5-1 |
| Aug 5, 2025 (view filing) | Aug 1 | 4 days | Ebsworth David RDirector | SSale | −1.90K | $13.14 | −$25.0K | −0.2%880.5K after |
Top 10 13F holders, Q3 2025
See all 243 holdersThe largest institutional positions in Verona Pharma plc at the end of Q3 2025; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Pentwater Capital Management LP | 5,300,000 | $565.6M | 5.08% | +5,300,000 | New |
| UBS Oconnor LLC | 4,283,462 | $457.1M | 13.74% | +4,283,462 | New |
| HBK Investments L P | 4,263,576 | $455.0M | 6.70% | +4,263,576 | New |
| BlackRock, Inc. | 3,826,710 | $408.3M | 0.01% | +3,483,014+1,013.4% | Added |
| FIL Ltd | 3,488,500 | $372.3M | 0.29% | +3,488,500 | New |
| Frazier Life Sciences Management, L.P. | 3,383,950 | $361.1M | 10.82% | 00.0% | Unchanged |
| Davidson Kempner Capital Management LP | 3,271,623 | $349.1M | 4.88% | +3,271,623 | New |
| Glazer Capital, LLC | 3,205,878 | $342.1M | 11.49% | +3,205,878 | New |
| NEA Management Company, LLC | 2,252,994 | $240.4M | 13.19% | −10,144−0.4% | Reduced |
| Goldman Sachs Group Inc | 1,935,278 | $206.5M | 0.03% | −682,019−26.1% | Reduced |
Holders of 5% or more of VRNA
See all 1 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Verona Pharma plc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock Portfolio Management LLC | 13G | 6.00%27.6M shares | New | Oct 17, 20251 filing | Oct 17, 2025 | SEC |